Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:47:53.722Z.
Calculation as of: 2026-10-06T16:47:53.722Z.
Quote observation: 2026-10-06T16:45:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$2.41B
EV/Sales Ratio
0.89x
TTM Avg
0.75x
3Y Avg
0.67x
5Y Avg
0.62x
Market Cap
$2.39B
EV/Sales Ratio
34.70x
TTM Avg
23.51x
3Y Avg
28.15x
5Y Avg
52.69x
Market Cap
$2.37B
EV/Sales Ratio
4.77x
TTM Avg
6.25x
3Y Avg
8.23x
5Y Avg
6.93x
Market Cap
$2.35B
EV/Sales Ratio
63.63x
TTM Avg
32.84x
3Y Avg
20.79x
5Y Avg
19.67x
Market Cap
$2.33B
EV/Sales Ratio
4.83x
TTM Avg
36.32x
3Y Avg
51.31x
5Y Avg
39.39x
Market Cap
$2.29B
EV/Sales Ratio
1.98x
TTM Avg
1.80x
3Y Avg
2.39x
5Y Avg
4.32x
Market Cap
$2.28B
EV/Sales Ratio
11.44x
TTM Avg
3.07x
3Y Avg
2.80x
5Y Avg
3.21x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.43B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | 0.89x | 0.75x | 0.67x | 0.62x |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.39B | 34.70x | 23.51x | 28.15x | 52.69x |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.39B | N/A | N/A | N/A | N/A |
| ADMA Biologics, Inc. (ADMA)vs › | $2.37B | 4.77x | 6.25x | 8.23x | 6.93x |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | 63.63x | 32.84x | 20.79x | 19.67x |
| Liquidia Corporation (LQDA)vs › | $2.33B | 4.83x | 36.32x | 51.31x | 39.39x |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.29B | 1.98x | 1.80x | 2.39x | 4.32x |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | 11.44x | 3.07x | 2.80x | 3.21x |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.59B | 303.77x | 165.08x | 106.18x | 84.28x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
